ENTITY
Federal Court Dismisses Novartis’ Challenge to Inflation Reduction Act, Marking Sixth Win for Government
Inflation Reduction Act, IRA lawsuit, Novartis, Medicare Drug Price Negotiation Program, federal court, pharmaceutical industry, government victory
HLTH24: Atropos Health Introduces AI-Powered Chat Co-Pilot for Rapid Real-World Evidence Generation
Atropos Health, HLTH24, Chat-Based AI Co-Pilot, Real-World Evidence, Generative AI, Healthcare Evidence Generation, GENEVA OS, ChatRWD
Amazon One Medical Introduces AI Tools to Enhance Primary Care Experience
Amazon One Medical, AI tools, primary care, healthcare technology, generative AI, patient care, administrative workload
Sangamo Therapeutics Fast-Tracks Fabry Gene Therapy with FDA Accelerated Approval Pathway
Sangamo Therapeutics, Fabry disease, gene therapy, isaralgagene civaparvovec, FDA, accelerated approval pathway, ST-920, STAAR study
Roche Abandons Tau Antibody Project, Returns Rights to UCB After $120M Investment
Roche, UCB, tau antibody, Alzheimer’s disease, bepranemab, $120M investment
Otsuka Seeks Accelerated Approval for Sibeprenlimab in IgA Nephropathy Following Positive Phase III Interim Results
Otsuka, sibeprenlimab, IgA nephropathy, Phase III trial, accelerated approval, FDA, kidney disease, autoimmune disease, APRIL antibody.
AvenCell Therapeutics Secures $112 Million Series B Funding for Revolutionary ‘Switchable’ CAR-T Cell Therapy
AvenCell Therapeutics, Series B Funding, CAR-T Cell Therapy, Switchable CAR-Ts, Clinical Trials, Biotech Innovation
Distinguishing Adverse Events from Complications in Heart Attacks
heart attack, adverse event, complication, cardiac health, medical emergency
Samsung Biologics Secures $1.2 Billion Production Contract, Boosting 2024 Deal Value to Over $3.3 Billion
Samsung Biologics, CDMO, Contract Manufacturing, Biopharmaceuticals, Production Contract, 2024 Deal Value
Starboard Value Criticizes Pfizer Leadership Over Underperforming R&D and Overpriced Acquisitions
Pfizer Inc., Starboard Value, Activist Investor, Pharmaceutical Industry, R&D Underperformance, Overpaid M&A Deals, Corporate Accountability